Introduction {#S1}
============

As a rule, drugs should not be used during pregnancy unless prescribed, because many can be toxic to the placenta or the developing fetus. Yet, the use of drugs, including prescription or non-prescription drugs, medicinal herbs, and licit (tobacco and alcohol) or illicit drugs, during pregnancy keeps increasing ([@B100]). Indeed, objective measurements of xenobiotics in meconium, amniotic fluid, and cord blood indicate widespread fetal exposure to such agents during their intrauterine life (for an excellent review see [@B7]). Such exposure may induce developmental adaptations that can be interpreted as derangements from normal development, which not only interfere with the immediate viability of the fetus but may also result in the individual's adverse health outcome in the short and long term ([@B48]; [@B6]). Hence, the "developmental origin of health and disease" hypothesis ([@B6]) stems from epidemiological studies showing that malnutrition, exposure to xenobiotics (e.g., environmental chemicals and prescription, legal, and illegal drugs), infective diseases, or stress during specific periods of development might increase the risk of disorders later in life. This hypothesis also stresses the importance of investigating the mechanisms of fetal exposure to xenobiotics and further in general to adverse intrauterine and perinatal factors.

In this minireview, we will provide an up-to-date analysis of the evidence for a sex differential in the susceptibility to the consequences of maternal drug use on neurocognitive and behavioral development of the offspring. Research has pointed to gender differences in these sequelae, since exposed males often appear more vulnerable than exposed females. Insights into the neurobiological mechanisms underlying the sex bias observed in certain neurobehavioral outcomes remain unidentified. At this stage, we could only make inferences from animal studies, although they do not allow for a precise understanding of the underpinnings, especially in the context of sex differences. In particular, many factors might moderate the reported sex dichotomy, including individual (e.g., species, strain, age) and experimental (e.g., design, drug, dosage, route, regimen) variables, and objective endpoints (e.g., behavioral paradigm, experimental technique). Here, we attempt to integrate the gender difference results across drugs used by pregnant women. Such integration could be useful for physicians and healthcare providers when caring for a pregnant substance abusing woman. Interspecies extrapolations will be carefully avoided to ensure sound conclusions. The authors refer to excellent preclinical studies' reviews ([@B15]; [@B103]; [@B98]; [@B44]; [@B21]; [@B102]).

Substance Use in Women {#S2}
======================

The historical gap in substance use prevalence between men and women has gradually narrowed in the past decade, particularly among adolescents ([@B61]; [@B104]; [@B111]; [@B33]). While women still exhibit lower rates of drug use disorder than men, prevalence rates indicate that the number of female drug abusers is on the rise. A recent snapshot of the European drug use situation shows that women account for one-quarter of the general population with drug issues and around one-fifth of all first-time drug abuse treatment seekers ([@B33]). Gender differences are clear in the pattern of use at each stage of the addiction cycle. Women typically begin to use substances later in life ([@B46]; [@B60]), misuse prescription drugs (e.g., opioids) ([@B80]), and their rate of consumption increases more rapidly than that of men ([@B46]; [@B60]). Women also exhibit higher prevalence rates of comorbidity with other psychiatric disorders as well as of relapse ([@B118]; [@B22]; [@B5]; [@B63]).

Drug Use During Pregnancy and Breastfeeding: Effects on Male and Female Offspring {#S3}
=================================================================================

The consumption of drugs in childbearing women has been progressively increasing. Women abusing recreational drugs before pregnancy tend to continue the use even during gestation ([@B39]), and this use is not limited to illegal drugs but includes prescription and over-the-counter drugs. Approximately 60% of pregnant women take prescription drugs and about 13% of them use herbal supplements. Furthermore, the infographics based on the National Survey on Drug Use and Health ([@B101]) show that 5.4% of pregnant women have used illicit drugs in the past 30 days, while 9.9 and 11.6% reported past-month alcohol or cigarette smoking use, respectively. To complicate this issue, many women take drugs when they are not aware of being pregnant.

Regardless of their legal status, all drugs cross and/or alter the placental barrier, reach the fetus, and affect infant development. Additionally, multiple drugs also pass into mother's breast milk, thus resulting in prolonged drug exposure of the newborn. According to the United States Centers for Disease Control and Prevention, almost 3% of newborns have birth defects because of genetic, environmental, or other unknown causes ([@B89]). Among environmental factors, drug use is the major cause leading to birth defects ranging from fetal growth reductions to medical complications such as preterm birth and infections. Furthermore, the progeny prenatally exposed to drugs of abuse develop neurobehavioral phenotypes that manifest during infancy and persist to adolescence and young adulthood. Research on the effects of prenatal alcohol, tobacco, opioids, stimulants, and cannabis indicates an association between fetal exposure to these substances and deficits in cognitive and behavioral domains. However, in humans, the role of fetal sex on functional consequences of prenatal exposure to drugs of abuse remains grossly understudied. Here we present data on illicit psychostimulants, opioids, cannabis, nicotine, and alcohol in an attempt to provide a clear picture of neurobehavioral outcomes in male and female progeny. When gender differences have not been examined, our interpretation is limited to the overall outcome.

Effects of *in utero* Exposure to Psychostimulants {#S3.SS1}
--------------------------------------------------

Psychostimulants, including cocaine and methamphetamine, are the illicit drugs most commonly used by childbearing women, though no recent estimate of their consumption during pregnancy is known. Despite their well-described neurotoxic effects on central nervous system (CNS) development, only very few studies have addressed the negative neurobehavioral sequalae on human offspring, particularly when gender is included as an additional biological variable ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

###### 

Detailed information on the studies covered in this minireview examining gender as a variable.

  --
  --

A thorough description of each study is presented with designed study type, experimental groups enrolled, outcomes, occurrence of poly-drug use, socioeconomic status, age at assessment, type of task used, and gender results. Gender effect is displayed as pink and blue for female and male progeny, respectively. Gender differences not observed are white.

![Heatmaps of neurobehavioral outcomes collectively identified as cognitive deficits (including executive function), ADHD risk, and behavioral problems, with missing information on gender differences shown in gray. Outcome intensities are displayed as colors ranging from pink (female) to blue (male) shown in the key. Gender differences were not observed in executive functions during childhood in offspring prenatally exposed to cocaine in one study only ([@B1]); therefore, the heatmap displays blue as a result of the larger number of consistent studies reporting that boys are more susceptible to exhibit deficits in cognitive abilities when compared to girls (see text and also [Table 1](#T1){ref-type="table"}).](fnbeh-14-00072-g001){#F1}

Longitudinal studies of long-term consequences of cocaine use during pregnancy on the offspring focusing on emotional regulation, behavior, and cognition suggest that female gender is a protective factor ([@B106]; [@B29]; [@B1]; [@B10]; [@B2]; [@B13]). Male progeny exhibit stronger impairment in inhibitory response, whereas females exhibit only mild alterations that disappear with age ([@B17]). Accordingly, male offspring exhibit greater emotion regulation problems and externalizing symptoms (e.g., aggressive and risky behaviors); lower intellectual capabilities; and deficits in attention, short-term memory, and problem solving compared to female offspring ([@B11], [@B9], [@B10]; [@B28]; [@B83]; [@B109]; [@B8]; [@B29]; [@B17]). In contrast, no gender dichotomy was found in the occurrence of attention deficit/hyperactivity disorder (ADHD) phenotypes from infancy to preadolescence ([@B58]; [@B77]; [@B79], [@B78]; [@B1]).

With regard to methamphetamine, the most frequent outcomes reported in newborns occur during the first year of life and include motor dysfunctions (e.g., disorganized behaviors with poor quality of movement), which tend to disappear with development in boys ([@B69]; [@B105]; [@B121]; [@B64]), whereas they persist throughout adolescence in girls ([@B35]; [@B18]). In contrast, other neurobehavioral problems (e.g., anxious/depressive phenotypes, emotional problems) appear during late infancy and childhood and do not exhibit sex bias ([@B69]). Similarly, impairments in cognitive skills occur equally in both female and male offspring ([@B72]; [@B93]; [@B30]). However, deficits in inhibitory control and ADHD-like symptoms are prevalent in boys ([@B69]; [@B65]).

Effects of Prenatal Exposure to Opioids {#S3.SS2}
---------------------------------------

Regardless of the efforts aimed at discouraging opioid use, prevalence rates show an increasing trend in pregnant women ([@B47]). However, gender was not considered in most of the human studies on the effects of heroin, methadone, and other prescription opioids.

Children born to mothers who use opioids during gestation suffer from the so-called neonatal opioid withdrawal syndrome (NOWS) ([@B45]), characterized by several signs and symptoms (e.g., tremors, sleep problems, hyperactive reflexes, vomiting, dehydration, and respiratory problems), which are more severe in boys than in girls ([@B55], [@B56]). Maternal consumption of methadone---the gold standard for opioid maintenance therapy---is associated with poorer cognitive performance and lower IQ scores in exposed males when compared to females during infancy, an age-dependent effect ([@B112]; [@B84]). However, no gender difference is found in symptoms related to ADHD and aggressive behavior up to preadolescence ([@B87]).

Effects of Maternal Tobacco {#S3.SS3}
---------------------------

Nicotine and its related tobacco products are the most studied substances in relation to long-term neurobehavioral outcomes in offspring exposed to tobacco during pregnancy. Despite the limitations due to several environmental confounding factors, a high degree of consistency exists for the association of maternal smoking and cognitive and behavioral problems (for an exhaustive review, see [@B34]). From these studies emerge a male bias toward diverse behavioral and cognitive domains, depending on age: at 6--8 months, males appear more vulnerable to deficits in cognitive and executive functions (e.g., inattention) and in motor functions and to alterations in reactivity ([@B81]; [@B115]; [@B120]). From infancy through childhood, boys appear at risk for ADHD ([@B67]; [@B23]; [@B120]; [@B3]; [@B53]); however, only during infancy do they display less positive mood ([@B92]) than females; during childhood and adolescence, males present more externalizing and disruptive behaviors (e.g., conduct disorders, antisocial behavior) than females ([@B116]; [@B36]; [@B53]). Conversely, parental tobacco exposure is associated with nicotine dependence and high consumption of tobacco only in adolescent girls ([@B99]). Although the risk of developing ADHD symptoms in nicotine-exposed progeny is high during adolescence, no gender differences were found ([@B43]; [@B3]; [@B110]).

Effects of Maternal Alcohol {#S3.SS4}
---------------------------

Despite the widely described dose-dependent teratogenic effect of alcohol ([@B66]; [@B86]), approximately 10% of women aged between 15 and 44 years consume alcohol during pregnancy, with 3% exhibiting a binge-drinking pattern ([@B100]). Irrespective of the amount and pattern of consumption, a wealth of clinical evidence describes that prenatal alcohol exposure markedly impairs cognitive, behavioral, and motor functions of offspring ([@B74]; [@B20]; [@B95]; [@B119]; [@B96]; [@B51]). Maternal moderate to heavy drinking produces a group of pathological conditions termed fetal alcohol spectrum disorder (FASD). Epidemiological studies report sexual dichotomy in FASD, with prevalence rates and severity being higher in male than in female patients ([@B76]; [@B4]; [@B113]; but see [@B75]; [@B40]). A sex bias is also described for other psychopathological traits, such as elevated rates of ADHD in 6- to 16-year-old boys but not girls ([@B20]; [@B50]). Boys also exhibit altered responses to stress, measured as larger changes in cortisol levels induced by stress-related cues ([@B49]). In contrast, neuroimaging studies do not reveal sex differences in long-term abnormalities of brain morphology because the reduction in both size and volume of frontal, temporal, cingulate, and striatal regions of offspring prenatally exposed to alcohol did not differ between genders ([@B31]; [@B114]; [@B26]). These findings suggest that such psychopathological traits cannot be attributed to these structural changes.

Effects of *in utero* Cannabis Exposure {#S3.SS5}
---------------------------------------

In line with the data on general population, the rates of cannabis use among pregnant women have markedly increased, with prevalence rates reaching 75% between 2002 and 2016 ([@B14]). Despite this alarming scenario, a few studies have assessed the long-term neurobehavioral repercussions of maternal cannabis use on the offspring, though gender differences were not consistently examined: the *Ottawa Prenatal Prospective Study* (OPPS), the *Maternal Health Practices and Child Development Project* (MHPCDP), the *Generation R* study, and *Adolescent Brain Cognitive Development* (ABCD) study. The OPPS study included gender as a confounding factor, and it described a number of long-lasting neurobehavioral alterations, ranging from heightened tremors and startle responsiveness to deficits in executive function (e.g., attention, cognitive flexibility, problem solving, impulse control) ([@B41]; [@B42]). Similarly, gender was not examined when assessing performance in memory, verbal, and perceptual processes as well as the first clinical signs of impulsivity at childhood ([@B108]). However, when the same authors subsequently included the gender factor on clinical signs that persisted at young adulthood, such as deficits in executive function tasks that require impulse control, they found no gender differences ([@B107]). In the MHPCD study, the authors seldom included "gender" in their analysis. However, they reported (1) significant sleep disturbances and deficits in mental development as well as in short-term memory and verbal reasoning at both 9 months and 3 years of age; (2) deficits in attention and memory, increased anxiety/depressive symptoms, impulsivity, hyperactivity, and aggression at 6 and 14 years of age ([@B94], [@B95]; [@B24]; [@B71]; [@B25]). Gender at 10 years of age did not affect cognitive deficits ([@B95]). In contrast, the Generation R study showed that girls but not boys at 18 months of age exhibited increased scores on an aggressive behavior scale that persisted through childhood ([@B32]). Notably, this sex bias disappears during adolescence. Also, during infancy girls appear to be at risk for the development of ADHD, a susceptibility that is age dependent ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Remarkably, although from Generation R and ABCD studies maternal cannabis use has been associated to proneness to psychosis in middle to late childhood, significantly earlier than the typical onset of first psychotic episode ([@B12]; [@B38]; [@B91]), again gender was not considered. Importantly, an independent investigation showed that prenatal marijuana exposure has an equally negative effect on sustained attention of the offspring from childhood to adolescence ([@B82]).

Conclusion {#S4}
==========

The literature here examined reveals gender differences in immediate and long-term negative consequences of maternal drug use on both cognition and behavior. When gender was included as a variable, irrespective of the drug used, male progeny appear more vulnerable to cognitive deficits and at risk of ADHD from infancy through childhood ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Notably, these gender differences tend to disappear with age. However, we cannot depict a clear picture for internalizing problems, drug use, and motor function deficits due to the paucity of data. Regarding the problems in the behavioral domain (i.e., externalizing problems), the current scenario is clearer: girls exposed *in utero* to cannabis are more vulnerable than boys up until adolescence, but this conclusion cannot be extended to other drugs. Remarkably, this is in contrast to what is often reported in rodent studies ([@B37]; [@B52]; [@B102]; [@B27]), where female sex often acts as a protective factor. Nevertheless, the advantage of animal studies is to dissect the effects of genetic, biological, and/or environmental risk factors. The establishment of a biological causality between prenatal drug exposure and repercussions on the progeny from animal investigations is pivotal. These mechanistic insights along with the observations reported in human studies may help in developing therapeutic interventions, on a gender-specific basis, which would ultimately result in more effective treatment outcome.

The longitudinal studies examined have often considered different factors that might have contributed to gender differences, including socioeconomic status, lifestyle indicators, stressful life events, social support (or lack thereof), and psychiatric comorbidity. In this regard, an additional degree of complexity arises from the evidence that single drug use is virtually non-existent. At this stage, we cannot certainly resolve this issue in human studies, as it deserves as much attention as neuroimaging and omics analyses to reveal neurobiological underpinnings of drug-exposed phenotypes. Of similar importance is the need to study the association between the perturbations of *in utero*--placental exchange and adverse mental health outcome later in life. Indeed, increasing evidence points to the role of the placenta in fetal programming, which is altered in response to prenatal insults and contributes to psychopathology ([@B16]; [@B62]; [@B97]; [@B88]; [@B68]). Notably, the placenta influences in a sex-dependent manner the outcome for offspring who were exposed to perinatal malnutrition and stressors ([@B117]). However, research into whether the gender bias results from sex differences in placental structure and functions or its genes, proteins, and steroids is surprisingly lacking. Hence, future research should aim at disentangling how sex impacts neurobiology from the transfer of maternal drug concentrations across the placenta to the effect on placental gene transcription or expression of discrete transporters (e.g., ATP-binding cassette carriers) in the cord. In fact, to date, such investigations have been performed only to relate maternal drug use and placental perturbations to fetal growth and other morphological abnormalities ([@B54]).

Substance (ab)use screening protocols, including questionnaires and urine toxicology testing, should be established worldwide as routine to identify pregnant women using drugs. Public health interventions regarding the awareness of the harm associated with maternal drug use, and special programs to enter treatment and/or increase spontaneous quit rates, should be implemented ([@B57]; [@B39] and references therein; [@B90]). Progress on tailored, safe, and acceptable pharmacotherapies to restore proper neurodevelopmental trajectories of the progeny should be incentivized. Additional preventative outreach programs should be implemented to raise community awareness and support and to provide access to treatment for the children who are prenatally exposed to drugs. Finally, future investigations should be implemented to include the influence of sex as a biological variable (for guidelines please refer to ([@B19]; [@B73]) in the outcome of offspring prenatally exposed to drugs of abuse.
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